Prezista

Indicated For

HIV infection

About This Medication

# Janssen Patient Assistance Program Guide: Getting Prezista at Low Cost ## What Is This Program? The Janssen Patient Assistance Program helps eligible patients access Prezista (darunavir) at little to no cost. Prezista is a prescription medication used to treat HIV infection. If you're struggling to afford this essential medication, this program may help you get the treatment you need. ## Who Can Apply? You may qualify if you meet one of these situations: - **Uninsured**: You have no health insurance - **Underinsured**: You have health insurance but it doesn't fully cover Prezista or your out-of-pocket costs are too high - **Any insurance type**: You have commercial insurance, employer-sponsored coverage, or government insurance (like Medicare or Medicaid) but still can't afford your medication ### Income Requirements Your household income must fall at or below 300% of the Federal Poverty Level (FPL). Income limits vary by family size and change annually. As a general guide: - **Single individual**: approximately $39,000–$40,000/year - **Family of 2**: approximately $52,000–$53,000/year - **Family of 3**: approximately $65,000–$66,000/year - **Family of 4**: approximately $79,000–$80,000/year Contact the program directly at **(833) 742-0791** to confirm current income limits for your household size. ## What Documents Do You Need? Before you call, gather these items: 1. **Proof of income**: Recent tax return, W-2, pay stub, or benefit statement 2. **Valid prescription**: A prescription for Prezista from your doctor 3. **Insurance information** (if applicable): Insurance card or policy details Having these ready will speed up your application. ## How to Apply **Step 1: Call the Program** Contact the Janssen Patient Assistance Program at **(833) 742-0791**. Phone lines are staffed to help you through the entire process. **Step 2: Provide Information** Tell the program representative about your situation, household income, and insurance status. Be prepared to share your documents (either over the phone or by mail). **Step 3: Submit Documentation** The program will tell you how to submit your proof of income and prescription. You can typically mail, fax, or upload documents online. **Step 4: Wait for Approval** The program will review your application and notify you of the decision. Once approved, you'll receive information on how to get your medication. ## Timeline: How Long Does This Take? Most applications are reviewed within **2 weeks** of receiving all required documents. However, if documents are missing or incomplete, the review may take longer. Once approved, you can typically start receiving medication within days. ## After You're Approved ### Medication Access Your Prezista will be shipped directly to you or your pharmacy at no cost (or very low cost, depending on your situation). ### Savings Card Option The program also offers a **savings card** if you have insurance and want to use it instead of the assistance program. This card may reduce your copay or coinsurance. ### Annual Reauthorization Your assistance is **not permanent**. You must reauthorize your eligibility **once per year**. The program will notify you when it's time to renew. Be ready to submit updated income documentation. ## Important Notes - **Medicare patients**: Yes, you can apply even if you have Medicare. The program helps with costs not covered by Medicare. - **No biosimilars available**: Prezista does not have a generic or biosimilar equivalent at this time. - **Your doctor's support**: Your doctor doesn't need to do anything special—just provide a valid prescription. ## Need Help? If you have questions at any point, call **(833) 742-0791**. The program staff can answer questions about eligibility, help you gather documents, and guide you through the entire process. **Website**: PatientAssistanceInfo.com Getting the HIV treatment you need shouldn't mean financial hardship. If cost is a barrier to taking Prezista, reach out to the Janssen Patient Assistance Program today.

Program information last verified: March 25, 2026